Moreover, very few of the patients developed anemia, a serious symptom of myelofibrosis.

FORBES: YM Biosicences: Its Data at ASCO On Drug for Bone Marrow Disorders Catapults Its Stock

The spooky thing about myelofibrosis is that nobody knows why it happens.

FORBES: MPN Research Foundation Is Awarding $100K Concept Grants To Combat Myelofibrosis

Incyte chief executive Paul Friedman says the company hopes to get data from a final-stage myelofibrosis trial in December that could lead to approval next year.

FORBES: The Next Big Rare Disease Drug?

Myelofibrosis is a disease that afflicts the bone marrow.

FORBES: MPN Research Foundation Is Awarding $100K Concept Grants To Combat Myelofibrosis

The treatment, CYT387, appears to demonstrate an ability to render and maintain myelofibrosis patients transfusion independent for clinically-relevant periods, while also improving other symptoms, according to a phase I and phase II study.

FORBES: Pharma News: Alexza Pharmaceuticals, YM BioSciences

Researchers from MD Anderson Cancer Center and elsewhere are reporting today in the New England Journal of Medicine that the Incyte drug, called INC424, improved symptoms of about 75% of 153 patients with myelofibrosis.

FORBES: The Next Big Rare Disease Drug?

The excitement over Canadian-based YM and its presentation of data from phase I and II clinical trials at ASCO centers not only on its positive data on myelofibrosis but on indications its JAK inhibitors may also have applications in solid tumors, as well as inflammatory diseases, says Chrystyna Bedrij, biotech analyst at Griffin Securities.

FORBES: YM Biosicences: Its Data at ASCO On Drug for Bone Marrow Disorders Catapults Its Stock